TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00325598

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Study: NCT00502502

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Weekly questionnaires lasting about 30 minutes.
Study: NCT00607672

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: Candesartan 16mg/d
Study: NCT01673789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator
Description: For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 \~ 9 hrs.
Study: NCT02529189

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: 70 ml of beetroot juice containing \~5 mmol of inorganic nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot Juice
Description: 70 ml of beetroot juice which is nitrate-depleted
Study: NCT01013545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JAE Intervention
Description: The overall goal in each session will be for the caregiver-child dyad to be in a state of supported or coordinated joint engagement. In this state the child is aware of the other's activity, and may actively coordinate their attention between an object/toy and the caregiver. The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JAE Intervention
Description: The overall goal in each session will be for the caregiver-child dyad to be in a state of supported or coordinated joint engagement. In this state the child is aware of the other's activity, and may actively coordinate their attention between an object/toy and the caregiver. The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist.
Study: NCT02339545

Intervention type: DEVICE
Intervention: Coronary Orbital Atherectomy plus Stenting
Study: NCT03629470

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Conservative Treatment
Description: Range of motion exercises, medication and activity modification.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Conservative Treatment
Description: Range of motion exercises, medication and activity modification.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve Gliding Exercises
Description: Taught by occupational therapist. These exercises involve motions of the wrist, arm and neck. Subjects will be instructed to perform exercises regularly following the occupational therapists' protocol
Study: NCT01796054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Free Now online program
Description: Stress Free Now is an online stress reduction program. Participants will log into online program, read and practice daily and weekly activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Free Now online program
Description: Stress Free Now is an online stress reduction program. Participants will log into online program, read and practice daily and weekly activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group support session
Description: Participants will meet weekly for group support session to review online lessons and relaxation therapies.
Study: NCT06544603

Intervention type: DEVICE
Intervention: Multiwave Locked System (MLS) laser
Description: Laser probe directly contacts with skin of the all the acupoints. The probe was fixed on each point for 1 min. In this study, the laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm)

Intervention type: DEVICE
Intervention: Multiwave Locked System (MLS) laser
Description: Laser probe directly contacts with skin of the all the acupoints. The probe was fixed on each point for 1 min. In this study, the laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm)
Study: NCT02905409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ILM peeling surgery
Description: 4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM peeling surgery
Description: 4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)
Study: NCT04443478

Intervention type: PROCEDURE
Intervention: Radical gastrectomy with dissection of lower mediastinal lymph node
Description: Radical gastrectomy for gastric cancer should be consistent with Japanese gastric cancer treatment guideline.

Intervention type: PROCEDURE
Intervention: Radical gastrectomy with dissection of lower mediastinal lymph node
Description: Radical gastrectomy for gastric cancer should be consistent with Japanese gastric cancer treatment guideline.
Study: NCT02398045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerised CBT for OCD
Description: Computerised CBT for OCD
Study: NCT00433017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
Study: NCT03840265

Intervention type: PROCEDURE
Group type: OTHER
Intervention: carotid endarterectomy
Description: In this project the following parameters will be assessed both in asymptomatic and symptomatic patients underwent carotid endarterectomy: 1) hemodynamic modeling of effect of the supraaortic arteries anatomic variations and pathologies 2, preoperative stroke risk prediction based on comparative analysis of CTA results of plaque morphology and ultrasound-based plaque elastography analysis, 3) cerebral flow measurement by transcranial Doppler sonography(TCD), 4) presence recent of silent brain ischemia on DWI-MRI, 5) OCT angiography could be a useful non-invasive method for evaluation of the outcome of carotid interventions
Study: NCT03531554

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketone ester drink
Description: 395 mg of ketone ester/kg

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise
Description: 35 min cycling test on an upright bicycle, followed by 10 minutes of supine cycling inside a MR scanner.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: 35 min cycling test on an upright bicycle, followed by 10 minutes of supine cycling inside a MR scanner.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: muscle biopsy
Description: biopsy from the quadriceps muscle prior to and immediately after upright bicycling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle biopsy
Description: biopsy from the quadriceps muscle prior to and immediately after upright bicycling

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: 1H MR images and 31P MR spectra were acquired from the upper leg prior to-, during and after exercise

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: 1H MR images and 31P MR spectra were acquired from the upper leg prior to-, during and after exercise
Study: NCT00894504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1500 mg/m2 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
Study: NCT02803593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-based information and coaching/support program
Description: The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources. The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers. The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship. The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: American Cancer Society information on breast cancer
Description: The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: American Cancer Society information on breast cancer
Description: The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
Study: NCT02577588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: re-activated T cells
Description: autologous reactivated T cells against p53
Study: NCT00224029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal system
Description: 3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
Study: NCT00433017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
Study: NCT01793350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BC-DN-01 topically applied cream
Description: Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
Study: NCT01109628

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink
Description: Twice a day during 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Twice a day during 6 months
Study: NCT05274087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous autoinjector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous autoinjector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous autoinjector
Study: NCT04112550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone Hydrochloride
Description: FDA approved medication to treat pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone-Acetaminophen
Description: FDA approved medication to treat pain
Study: NCT02006433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Local anesthesis, MRI and CT scan of the brain followed by implantation of the stimulation device
Study: NCT00885378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin plus metformin IR
Description: Tablets, Oral, 2.5 mg, Twice daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus metformin IR
Description: Tablets, Oral, Placebo, Twice daily, 12 weeks
Study: NCT04379765

Intervention type: BEHAVIORAL
Intervention: Exercise and physical therapy
Description: Decompression operation
Study: NCT01759394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag maleate 40 mg
Description: Avatrombopag maleate 40 mg (2 x 20 mg tablets- all doses are expressed as avatrombopag, the amount of free base) given with 240 mL water in three single oral doses, one during each of three treatment periods. Participants randomized to one of three treatment sequences:~* Fed, Fed, Fasted; or~* Fed, Fasted, Fed; or~* Fasted, Fed, Fed~During the Fasted period, participants must have fasted for at least a 10-hour overnight fast and to refrain from eating for 4 hours.~During the Fed period, participants were allowed approximately 30 minutes to eat a low-fat breakfast and required to take the drug within 15 minutes of completion of breakfast.~Randomization Phase consists of three single-dose treatment periods:~Treatment Period 1 and 2 separated by a 7-day washout interval. Treatment Period 2 and 3 separated by a 28-day washout interval. Treatment period 3 and the Follow-up/ Termination Visit will be separated by a 30-day (+1 day) washout interval.
Study: NCT04193553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for dose reductions will be respected according to BI Lenvatinib.~If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for placebo dose reductions are the same as for Lenvatinib. If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met.~In case disease progression, patients in control arm could switch in the Lenvatinib + BSC arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: At any time during the study, patients should receive best supportive care. Best Supportive care as medically indicated for the patient's well-being may be prescribed at the investigator's discretion. Based on the patient's condition, it may consist (but not limited) of analgesics, antibiotics, steroids, blood transfusion, antiemetics, antidepressants/anxiolytics, nutritional counselling, psychological support, palliative radiotherapy...

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best supportive care
Description: At any time during the study, patients should receive best supportive care. Best Supportive care as medically indicated for the patient's well-being may be prescribed at the investigator's discretion. Based on the patient's condition, it may consist (but not limited) of analgesics, antibiotics, steroids, blood transfusion, antiemetics, antidepressants/anxiolytics, nutritional counselling, psychological support, palliative radiotherapy...
Study: NCT00060372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Given IV
Study: NCT02812225

Intervention type: DEVICE
Intervention: BrainPulse
Description: Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
Study: NCT01760213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT delivered via Internet
Study: NCT01658254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey by email
Description: The intervention consists in an email to be sent to the sponsor and/or principal investigator of randomly assigned trials. This email will notify them that their trial's primary completion date is over a year old and will ask the reasons why they have not posted results on the registry. Several reasons will be proposed, and investigators or sponsors will be asked to reply by sending back an email or through a website where the same questions will appear. A follow-up email will systematically be sent 7 days after, with similar content (appendix2). The emails will be sent as direct emails, without attached files, with the edit subject Posting basic results. The controlled group will receive no intervention.
Study: NCT01709409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curosurf-Group1
Description: Maximum of 3 doses are administered to infants diagnosed with RDS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BLES-group 2
Description: Maximum of 3 doses are administered to infants with RDS
Study: NCT03278847

Intervention type: DIETARY_SUPPLEMENT
Intervention: Received enteral (milk) feeds during therapeutic hypothermia
Description: In the enteral component of nutrition, the health technology to be assessed is the gradual introduction of enteral (milk) feeds during therapeutic hypothermia:~* Included in this is any type of milk (e.g. expressed maternal breast milk, expressed donor breast milk and artificial formula)~* This health technology includes different routes of administering enteral feeds such as nasogastric tube (gavage feeding) and bottle~* This health technology also includes different rates of increasing enteral feeds (for example by 15ml/kg/day, by 30ml/kg/day or faster)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Enteral (milk) feeds withheld during therapeutic hypothermia
Description: Withholding enteral feeds (keeping a baby nil per os) for the duration of hypothermia.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Received parenteral nutrition during therapeutic hypothermia
Description: In the parenteral component, the health technology being assessed is administration of parenteral nutrition during therapeutic hypothermia:~* Included in this are different compositions of parenteral nutrition (for example standard, pre-prepared bags of nutrition and individually tailored parenteral nutrition)~* This health technology includes different routes of administration of parenteral nutrition such as via a peripheral intravenous cannula, percutaneous central venous catheter ('long line') or umbilical venous catheter.~* This health technology also includes different volumes of parenteral nutrition (e.g. 40ml/kg/day, 60ml/kg/day or greater).

Intervention type: DIETARY_SUPPLEMENT
Intervention: Did not receive parenteral nutrition during therapeutic hypothermia
Description: Received standard intravenous fluids (10% dextrose with additional electrolytes added where required) for the duration of hypothermia.
Study: NCT03635086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK lyophilised formulation, low dose
Description: MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, lyophilized low dose (powder for suspension in water for intramuscular \[IM\] injection): 5x10\^4 ±0.5 log tissue culture infectious dose 50 (TCID50)/dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK liquid frozen formulation, low dose
Description: MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen low dose (suspension for IM injection): 1x10\^5 ±0.5 log TCID50/dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK SPS® formulation, low dose
Description: MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid SPS® low dose (suspension for IM injection): 1x10\^5 ±0.5 log TCID50/dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK liquid frozen formulation, high dose
Description: MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen high dose (suspension for IM injection): 1x10\^6 ±0.5 log TCID50/dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK liquid frozen formulation, high dose
Description: MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen high dose (suspension for IM injection): 1x10\^6 ±0.5 log TCID50/dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile physiological saline solution (0.9% sodium chloride \[NaCl\]), administered by IM injection.
Study: NCT03569592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overdose Prevention Intervention
Description: Evaluate an overdose prevention education with incarcerated people living with HIV/AIDS.
Study: NCT03494465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PHACOEMULSIFICATION
Description: Standard phacoemulsification with intraocular lens implant will be perform within 60 days after allocation. If IOP target is not achieve, patients will be treated as in medical treatment group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDICAL GLAUCOMA TREATMENT
Description: The escalation of topical hypotensive medications will be carried out with the following sequence: 1. single topical medication; 2. double topical therapy; 3. triple topical therapy. Beginning, with the exception of individual contraindications, with prostaglandin analogs, followed by topical beta-blockers, carbonic anhydrase inhibitors and finally alpha-agonists.Target IOP will be used in both groups to inform the need of escalation of therapy; in patients with ocular hypertension the target IOP will be 21 mmHg. In patients with mild glaucoma target IOP will be 18 mmHg, and in patients with moderate glaucoma the target IOP will be 15 mmHg.
Study: NCT02001909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: single oral dose (s.d.) 160 mg (four 40 mg tablets) of regorafenib on two occasions (Day 1, Period 1, and Day 1, Period 2) separated by a washout period of at least 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: 1 g tid (three times a day) regimen of Neomycin (oral) on five days in Period 2 starting 4 days before regorafenib intake on day 1 in period 2.